[ET Net News Agency, 27 January 2022] Daiwa lowered its target price for Innovent Bio
(01801) to HK$48 from HK$67 and maintained its "outperform" rating.
The research house said it does not see Innovent Bio making any significant clinical
progress in 2022. (RC)